US 10532096
Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10532096 (Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K38/179, A61K38/1793